Baidu
map

NEJM:全球阿片类药物滥用趋势分析报告

2015-01-26 王国彪 译 医学论坛网

【1月26日讯】一项监测2002年—2013年间阿片类药物滥用趋势的研究显示,阿片类止痛药处方、阿片类转移和滥用以及阿片类相关死亡在2002年—2010年呈上升趋势。 然而,在2001年—2013年间上述三项测量指标呈平稳或下降的趋势。 “这表明美国对阿片类药物滥用作出了努力,而且干预措施确实见效了。”科罗拉多州丹佛卫生署及医院管理局药品中心主任、本研究的主要作者理查德·达特博士向

【1月26日讯】一项监测2002年—2013年间阿片类药物滥用趋势的研究显示,阿片类止痛药处方、阿片类转移和滥用以及阿片类相关死亡在2002年—2010年呈上升趋势。

然而,在2001年—2013年间上述三项测量指标呈平稳或下降的趋势。

“这表明美国对阿片类药物滥用作出了努力,而且干预措施确实见效了。”科罗拉多州丹佛卫生署及医院管理局药品中心主任、本研究的主要作者理查德·达特博士向Medscape医学新闻表示。

“我们并不知道为何会出现这样的情况,但看上去它与其他来源的相关性良好,”达特博士补充说,“它并没有真的下降,至少曲线的斜率显著改变,不再增长。”

该研究 在线发表 于1月15日的《新英格兰医学杂志》。

死亡例数巨大

在2010年,美国总共有16,651例死亡归因于阿片类处方。调查者报告说。

“基于此,数以百计的联邦、州府和地方干预开始实施。例如,49个州已经通过立法建立处方药监测方案。”他们写道。

然而,“约在2011年,我们注意到处方药滥用的斜率在所有监测方案中在增长10年的趋势下开始变得平稳。我们注意到并认为,可能存在一些其它原因,但之后比率还是下降了。”达特博士说。

“我们想用一两年的时间来确定观测结果的正确,而不仅仅代表一或两个季度的特征。”他补充道。

研究者们检测了来自滥用、转移和成瘾相关监视系统(RADARS)中2002-2013年的数据。为确定其趋势,他们评估了五项RADARS。它们包括如下内容:

毒物中心计划

药物分流方案

阿片类药物治疗方案

患者关键信息(SKIP)的调查程序

学院调查程序

研究者写道,“因为药物滥用是非法活动,常常避开官方。RADARS系统采用了”马赛克“的方法,以此从多角度测量滥用和转移。”

以下六种阿片类镇痛药处方被列入本次搜索中:氢可酮,吗啡,芬太尼,吗啡,羟考酮,和曲马多。此外,在过去30天的海洛因使用数据包括RADARS程序询问该物质。

原始文章提供财务关系的完整列表报告。

原始出处:

Dart RC1, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL.Trends in opioid analgesic abuse and mortality in the United States.N Engl J Med. 2015 Jan 15;372(3):241-8. doi: 10.1056/NEJMsa1406143.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得看,谢谢分享,值得收藏、转发,很全面

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
    2015-03-23 zchen
  3. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
    2015-02-03 tutu159

    总结很全面

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
    2015-01-28 lhlxtx
  8. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=48006, encodeId=dc4e4800603, content=值得看,谢谢分享,值得收藏、转发,很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701505, encodeId=14c51e0150594, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Mar 23 22:52:00 CST 2015, time=2015-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667547, encodeId=e76a166e5476a, content=<a href='/topic/show?id=b9559296103' target=_blank style='color:#2F92EE;'>#趋势分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92961, encryptionId=b9559296103, topicName=趋势分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20bf26147921, createdName=bugit, createdTime=Sat Oct 17 23:52:00 CST 2015, time=2015-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992350, encodeId=ad1719923500c, content=<a href='/topic/show?id=a9ea31e618d' target=_blank style='color:#2F92EE;'>#分析报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31761, encryptionId=a9ea31e618d, topicName=分析报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Wed Apr 08 09:52:00 CST 2015, time=2015-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15023, encodeId=b7bb1502371, content=总结很全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Tue Feb 03 19:19:00 CST 2015, time=2015-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252988, encodeId=18e21252988a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308998, encodeId=217a13089983c, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443222, encodeId=1d39144322260, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Wed Jan 28 05:52:00 CST 2015, time=2015-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14734, encodeId=7a0914e3434, content=很多这种情况!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Jan 27 09:24:00 CST 2015, time=2015-01-27, status=1, ipAttribution=)]
    2015-01-27 MedSci客户端网友

    很多这种情况!

    0

相关资讯

ERRM:阿片类药物治疗难治性呼吸困难

难治性呼吸困难是指在积极治疗原发病的前提下,在静息或轻微体力活动后仍出现呼吸困难症状。内源性(β- 内啡肽)和外源性(吗啡)阿片类药物可通过与阿片受体结合改善呼吸困难症状。 阿片类药物缓解难治性呼吸困难可能的机制包括:呼吸驱动联合伴随放电的减少、中枢感知的改变、肺部外周阿片类受体活性改变及焦虑症状改善。 由于患者对于阿片类药物的治疗效果不尽相同,一般从小剂量开始缓慢增加,直到达到病人认为能

肠麻醉综合征的全新共识

引言 40%的成年人患有慢性疼痛,导致生活质量下降、工作时间缩短及相关的间接花费,如仅在美国每年由此导致的花费高达600亿美元。阿片类药物广泛应用于中至重度癌性及非癌性疼痛。现在临床医生、患者及社会统一认为缓解疼痛十分重要,因此阿片类药物的应用将会增加。如在美国,高达3%的成年人因慢性非癌性疼痛需服用阿片类药物镇痛治疗,每年有高达250,000,000份相关的处方 阿片类药物相

Chest:阿片类药物和某些非阿片类药物可有效治疗成人慢性咳嗽

了解不同疗法对不明原因咳嗽、或顽固性咳嗽的相对效果,有助于加深人们对这一独特群体中各疗法的效果及其潜在不良反应的认识。为此,来自美国北卡罗莱那州杜克大学医学中心医学部的William博士等人进行了一项研究,研究结果在线发表于2013年8月8日的CHEST杂志上。研究发现,阿片类药物和某些非阿片类/非麻醉性止咳药对成人慢性咳嗽的治疗有明确效果。【原文下载】 该研究是一项文献荟萃分析性研究。研究者对

JAAOS:长期使用阿片类药物患者骨科手术时的疼痛管理

阿片类药物在骨骼肌肉疼痛的临床治疗中应用较多。但是,阿片药物使用较长时间较多的副作用,对有长期阿片类药物使用病史的患者,围手术期的疼痛控制是一个难点。 对这类患者需进行仔细的评估,包括术前患者的阿片类药物使用量,患者对疼痛相关的敏感程度,是否有潜在的精神或心理疾病等。对大剂量使用阿片药物的患者,需请专科医生评估是否存在成瘾性的可能。多种局部阻滞麻醉和药物止痛方法可以用来改善围手术期疼痛,

孕期使用阿片类药物增加致畸风险

【1月26日讯】 今天,美国疾病控制和预防联邦卫生官员公布:“阿片类治疗疼痛药物在女性分娩时被广泛使用,是一个"严重的公众健康问题"”。 一项在1月13日发表于《发病率和死亡率周报 (MMWR)》 的研究显示,在2008至2012年间,约四分之一的被私人保险覆盖的女性,她们的年龄介于15—44岁之间;约三分之一的被医疗补助覆盖的患者每年都在按照阿片类处方服药。 “在孕期服用阿片类

JAMA:服用阿片类药物的老年患者住院率连年升高

卫生保健研究与质量管理局(AHRQ)研究了1993年到2012年服用阿片类止疼药的成人住院率情况,结果发现,85岁及以上患者住院率居首位,65~84岁患者位居第二,45~64岁患者位居第三。而且,医疗保险的理赔也随此住院率迎来最大的增长率,占所有住院治疗的30%,这是1993年的一倍。 这是一个重要的公共卫生问题 NIH的官员指出,对于阿片类药物,特别是老年患者,已经出现过度依赖的状况

Baidu
map
Baidu
map
Baidu
map